ADMA Historical Income Statement
| ADMA Stock | USD 17.40 0.50 2.79% |
Historical analysis of ADMA Biologics income statement accounts such as Other Operating Expenses of 248.4 M, Operating Income of 22.7 M or Total Operating Expenses of 69.9 M can show how well ADMA Biologics performed in making a profits. Evaluating ADMA Biologics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of ADMA Biologics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining ADMA Biologics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ADMA Biologics is a good buy for the upcoming year.
ADMA |
About ADMA Income Statement Analysis
ADMA Biologics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to ADMA Biologics shareholders. The income statement also shows ADMA investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
ADMA Biologics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of ADMA Biologics. It is also known as ADMA Biologics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Depreciation And Amortization
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.Total Revenue
Total revenue comprises all receipts ADMA Biologics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of ADMA Biologics minus its cost of goods sold. It is profit before ADMA Biologics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Most accounts from ADMA Biologics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into ADMA Biologics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ADMA Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.At present, ADMA Biologics' Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Other Operating Expenses is expected to grow to about 248.4 M, whereas EBIT is forecasted to decline to (3.4 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Cost Of Revenue | 79.8M | 118.8M | 169.3M | 177.7M | Research Development | 3.6M | 3.6M | 3.3M | 4.4M |
ADMA Biologics income statement Correlations
Click cells to compare fundamentals
ADMA Biologics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ADMA Biologics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 9.0M | 12.0M | 13.1M | 19.3M | 25.0M | 26.3M | |
| Other Operating Expenses | 70.8M | 107.1M | 139.3M | 193.4M | 236.6M | 248.4M | |
| Operating Income | (41.4M) | (64.9M) | (58.4M) | (39.4M) | 21.6M | 22.7M | |
| Ebit | (41.4M) | (63.8M) | (58.8M) | (46.8M) | (3.2M) | (3.4M) | |
| Total Operating Expenses | 31.3M | 45.8M | 59.5M | 74.6M | 66.6M | 69.9M | |
| Income Before Tax | (48.3M) | (75.7M) | (71.6M) | (65.9M) | (28.2M) | (29.7M) | |
| Net Income | (57.0M) | (87.6M) | (84.5M) | (85.2M) | (28.2M) | (29.7M) | |
| Selling General Administrative | 25.9M | 35.1M | 55.2M | 70.3M | 57.4M | 60.2M | |
| Ebitda | (40.0M) | (59.8M) | (53.3M) | (39.7M) | 5.1M | 5.4M | |
| Depreciation And Amortization | 1.4M | 3.9M | 5.5M | 7.1M | 8.3M | 8.7M | |
| Total Other Income Expense Net | (6.9M) | (10.8M) | (13.5M) | (26.8M) | (49.9M) | (47.4M) | |
| Income Tax Expense | 8.8M | 11.9M | 12.8M | 19.3M | 8.2M | 5.9M | |
| Total Revenue | 29.3M | 42.2M | 80.9M | 154.1M | 258.2M | 271.1M | |
| Gross Profit | (10.2M) | (19.1M) | 1.2M | 35.3M | 88.9M | 93.4M | |
| Net Income From Continuing Ops | (48.3M) | (75.7M) | (71.6M) | (65.9M) | (22.8M) | (24.0M) | |
| Research Development | 2.3M | 5.9M | 3.6M | 3.6M | 3.3M | 4.4M | |
| Cost Of Revenue | 39.5M | 61.3M | 79.8M | 118.8M | 169.3M | 177.7M | |
| Non Operating Income Net Other | 2.1M | 1.2M | (217.0K) | (7.3M) | (6.5M) | (6.2M) | |
| Net Income Applicable To Common Shares | (48.3M) | (75.7M) | (71.6M) | (65.9M) | (59.3M) | (62.3M) | |
| Interest Income | 800.8K | 288.1K | 34.5K | 44.8K | 1.0M | 1.1M | |
| Net Interest Income | (8.2M) | (11.7M) | (13.0M) | (19.2M) | (23.5M) | (22.4M) | |
| Reconciled Depreciation | 3.3M | 3.9M | 5.5M | 7.1M | 8.2M | 5.4M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ADMA Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ADMA Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Adma Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Adma Biologics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ADMA Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADMA Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 14 | Earnings Share 0.27 | Revenue Per Share 1.661 | Quarterly Revenue Growth 0.781 | Return On Assets 0.1989 |
The market value of ADMA Biologics is measured differently than its book value, which is the value of ADMA that is recorded on the company's balance sheet. Investors also form their own opinion of ADMA Biologics' value that differs from its market value or its book value, called intrinsic value, which is ADMA Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADMA Biologics' market value can be influenced by many factors that don't directly affect ADMA Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ADMA Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ADMA Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.